January 11-14, 2027 | San Francisco
2027 Participating Companies
EicOsis is developing inhibitors of soluble epoxide hydrolase (sEHI) as a unique validated approach to chronic inflammatory disease. Our lead sEHI, EC5026, has completed Phase 1 clinical development with a safety profile supporting once-daily doses.